CVRx Inc. will attend the Technology and Heart Failure Therapeutics 2026 (THT) annual meeting on March 2-4, 2026, in Boston, and will host a CVRx-sponsored satellite program on March 3, 2026 (12:15-1:30 p.m. ET) in Ensemble CD South featuring updates on Barostim outcomes, including REBALANCE Registry results and the BREATHE-HF and BENEFIT-HF trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020830PRIMZONEFULLFEED9662939) on March 02, 2026, and is solely responsible for the information contained therein.